The Activity of Polyhomoarginine against Acanthamoeba castellanii

Hari Kumar Peguda1, Rajamani Lakshminarayanan2,3,4, Nicole A Carnt1

  • 1School of Optometry and Vision Science, University of New South Wales, Sydney 2052, Australia.

Biology
|December 23, 2022
PubMed

Insights

Polyhomoarginines (PHAs) show potent anti-amoeba activity against Acanthamoeba castellanii, inhibiting both trophozoites and cysts. PHA 10 demonstrated excellent efficacy and low toxicity, suggesting potential for treating Acanthamoeba keratitis.

Area of Science:

  • Microbiology
  • Parasitology
  • Biochemistry

Background:

  • Arginine-rich peptides exhibit broad-spectrum antimicrobial properties.
  • Polyhomoarginines (PHAs) possess highly cationic residues effective against microbial cell membranes.
  • Acanthamoeba castellanii causes difficult-to-treat Acanthamoeba keratitis.

Purpose of the Study:

  • To evaluate the anti-amoeba activity of polyhomoarginines (PHAs) against Acanthamoeba castellanii.
  • To assess the efficacy of PHAs against both trophozoite and cyst forms of Acanthamoeba.
  • To determine the safety profile of PHAs concerning host cell toxicity.

Main Methods:

  • Acanthamoeba amoebicidal, amoebistatic, encystation, and excystment assays were conducted.
  • Polyhomoarginines of varying lengths (10-400 residues) were tested at concentrations from 0.93 μM to 15 μM.
  • Data analysis involved one-way ANOVA, with haemolysis assays for toxicity assessment.

Main Results:

  • PHAs demonstrated significant anti-acanthamoeba activity against both trophozoites and cysts.
  • PHA 30 (3.75 μM) reduced trophozoites by 99%, inhibited cyst formation by 96%, and excystment by 67%.
  • PHA 10 (15 μM) showed comparable activity, reducing trophozoites by 98%, inhibiting cyst formation by 84%, and excystment by 99% with minimal haemolysis.

Conclusions:

  • Polyhomoarginine 10 exhibits excellent anti-amoebic activity and low toxicity against Acanthamoeba castellanii.
  • PHAs show promise as a potential therapeutic agent for Acanthamoeba keratitis.
  • Further pre-clinical and in vivo studies are warranted to validate therapeutic potential.